Tag Archive for: CAR-T

Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering

/in

Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM  London, UK and Chicago, IL – 15 December 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, and Syenex, an open-science genetic medicines platform company, today announced a strategic collaboration […]

Read more

Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturing

/in

Agreement with Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) for the manufacturing of CAR-T therapies using Lakhesys Benchtop Cell FactoryTM Partnership to demonstrate the ability of Astraveus’ technology to deliver reduced costs and increased efficiency in CAR-T manufacturing Paris, France, 6 May 2025 – Astraveus SAS (“Astraveus” or the […]

Read more

Astraveus opens path to accessible cell therapies with first ever end-to-end microfluidic CAR-T production

/in

Paris, France, 9 January 2025 – Astraveus SAS (“Astraveus” or the “Company”), the Benchtop Cell Factory company, today announces the first ever successful end-to-end production of CAR-T cells within a microfluidic benchtop system. Using its fully automated Lakhesys Benchtop Cell FactoryTM, Astraveus has been able to demonstrate the potential of its unique microfluidic cell therapy processing […]

Read more

Leucid Bio to Participate in Upcoming Healthcare Conferences

/in

London, UK – 31 October 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced that management will be participating in the following upcoming investor conferences during the month of November: BIO-Europe at Messe […]

Read more

Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR T-Cell Therapy LEU011

/in

Company on-track to dose first patient in LEU011 Phase 1/2 AERIAL trial during the fourth quarter of 2023 Lead programme, LEU011 previously awarded an Innovation Passport by MHRA for the treatment of solid tumours expressing NKG2D ligands London, UK – 21 September 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing […]

Read more